JP2024508706A5 - - Google Patents

Info

Publication number
JP2024508706A5
JP2024508706A5 JP2023548552A JP2023548552A JP2024508706A5 JP 2024508706 A5 JP2024508706 A5 JP 2024508706A5 JP 2023548552 A JP2023548552 A JP 2023548552A JP 2023548552 A JP2023548552 A JP 2023548552A JP 2024508706 A5 JP2024508706 A5 JP 2024508706A5
Authority
JP
Japan
Prior art keywords
composition
composition according
copper
prepared
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016205 external-priority patent/WO2022174094A1/en
Publication of JP2024508706A publication Critical patent/JP2024508706A/ja
Publication of JP2024508706A5 publication Critical patent/JP2024508706A5/ja
Pending legal-status Critical Current

Links

JP2023548552A 2021-02-11 2022-02-11 近視の治療 Pending JP2024508706A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148344P 2021-02-11 2021-02-11
US63/148,344 2021-02-11
PCT/US2022/016205 WO2022174094A1 (en) 2021-02-11 2022-02-11 Treatment of myopia

Publications (2)

Publication Number Publication Date
JP2024508706A JP2024508706A (ja) 2024-02-28
JP2024508706A5 true JP2024508706A5 (cg-RX-API-DMAC7.html) 2025-02-20

Family

ID=82837328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548552A Pending JP2024508706A (ja) 2021-02-11 2022-02-11 近視の治療

Country Status (9)

Country Link
US (1) US20240122974A1 (cg-RX-API-DMAC7.html)
EP (1) EP4291163A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024508706A (cg-RX-API-DMAC7.html)
KR (1) KR20240021734A (cg-RX-API-DMAC7.html)
CN (1) CN118234482A (cg-RX-API-DMAC7.html)
AU (1) AU2022220331A1 (cg-RX-API-DMAC7.html)
CA (1) CA3208185A1 (cg-RX-API-DMAC7.html)
TW (1) TW202302121A (cg-RX-API-DMAC7.html)
WO (1) WO2022174094A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11524032B2 (en) * 2018-01-05 2022-12-13 University Of Utah Research Foundation Treatment of myopic progression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058015A1 (en) * 2000-06-01 2004-03-25 Yuanjin Tao Compositions and methods for treating eye discomfort and eye disease
US20040001791A1 (en) * 2000-11-16 2004-01-01 Zeiler Kenneth T. Composition, method of use, and devices for the treatment of onychomycosis
US9504603B2 (en) * 2012-04-02 2016-11-29 Ocuject, Llc Intraocular delivery devices and methods therefor
CA3246118A1 (en) * 2013-10-07 2025-02-21 Ocuject, Llc Intraocular delivery devices and methods therefor
ES2959242T3 (es) * 2016-03-08 2024-02-22 Univ Utah Res Found Agentes de reticulación y métodos asociados
US11524032B2 (en) * 2018-01-05 2022-12-13 University Of Utah Research Foundation Treatment of myopic progression
CN109776623B (zh) * 2019-03-05 2021-05-07 潍坊科技学院 一种含氟草酰胺同/异核化合物的制备方法与应用

Similar Documents

Publication Publication Date Title
JP2023105147A5 (cg-RX-API-DMAC7.html)
TWI361701B (en) Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye
JP2019524826A5 (cg-RX-API-DMAC7.html)
CN102164592B (zh) 可与核黄素一起使用的增强剂制备用于在圆锥角膜的治疗中进行角膜交联的眼用组合物的用途以及相应眼用组合物
CA2672985C (en) Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia
CA2987787C (en) Compositions for the improvement of distance vision and the treatment of refractive errors of the eye
Dugel et al. Pars plana vitrectomy for intraocular inflammation-related cystold macular edema unresponsive to corticosteroids a preliminary study
EP1904108B1 (en) Ophthalmological formulation comprising methylsulfonylmethane and ciprofloxacin
JP2021509902A5 (cg-RX-API-DMAC7.html)
CA2806942C (en) Compounds for the treatment/prevention of ocular inflammatory diseases
US20060177430A1 (en) Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20060172972A1 (en) Formulation and method for administration of ophthalmologically active agents
JP7795555B2 (ja) 近視を治療するための方法及び薬物組成物
US20220257593A1 (en) Carabachol-bromonidine formulation to enhance anti-presbyopia effects
US20060166879A1 (en) Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
TW202333700A (zh) 用於治療眼病之組成物及方法
US20220175734A1 (en) Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
WO2020062445A1 (zh) 防治nitm的药物组合物及其医药用途
Macsai et al. Keratoconus and Turner's syndrome
JP2021534217A5 (cg-RX-API-DMAC7.html)
JP2022541152A5 (cg-RX-API-DMAC7.html)
Hamilton et al. Filamentary keratitis
Fourman Acute closed-angle glaucoma after arteriovenous fistulas
US20230210821A1 (en) Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
Mueller et al. Serous retinal detachment in a patient with a port-wine birthmark associated with prostaglandin analog therapy